当前位置:首页 - 行情中心 - 东宝生物(300239) - 财务分析 - 利润表

东宝生物

(300239)

  

流通市值:34.27亿  总市值:34.49亿
流通股本:5.90亿   总股本:5.94亿

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入532,797,977.19369,055,800.99188,034,307.73884,932,215.88
  营业收入532,797,977.19369,055,800.99188,034,307.73884,932,215.88
二、营业总成本479,925,097.45327,726,411.88165,982,769.88784,300,105.92
  营业成本402,128,895.05275,176,850.03140,917,714.68683,859,412.69
  税金及附加8,121,413.385,389,593.692,601,869.289,809,271.24
  销售费用13,505,319.559,435,417.363,973,926.3618,695,645.02
  管理费用36,123,934.7724,413,751.712,990,219.5749,965,485.13
  研发费用18,907,749.3212,476,486.445,722,250.8527,361,788.76
  财务费用1,137,785.38834,312.66-223,210.86-5,391,496.92
  其中:利息费用3,151,033.472,268,836.6726,987.632,564,535.38
  其中:利息收入1,980,268.151,343,190.4831,304.147,114,485.65
三、其他经营收益
  加:投资收益-2,163,655.2-1,566,045.78-576,059.12-3,743,341.08
  资产处置收益-75,476.56-90,612.6110,571.31-284,115.61
  资产减值损失(新)-4,747,143.37-3,128,326.29-1,519,552.08-3,316,535.41
  信用减值损失(新)369,080.85336,794.19137,864.54525,527.93
  其他收益9,123,188.455,144,013.212,188,036.2112,367,917.13
四、营业利润55,378,873.9142,025,211.8322,292,398.71106,181,562.92
  加:营业外收入735,566.53413,287.68142,580.56341,822.39
  减:营业外支出219,346.2837,161.131,907.09890,408.01
五、利润总额55,895,094.1642,401,338.3822,433,072.18105,632,977.3
  减:所得税费用7,447,458.665,434,215.233,388,371.4414,368,848.66
六、净利润48,447,635.536,967,123.1519,044,700.7491,264,128.64
(一)按经营持续性分类
  持续经营净利润48,447,635.536,967,123.1519,044,700.7491,264,128.64
(二)按所有权归属分类
  归属于母公司股东的净利润48,449,538.0536,967,330.2319,044,819.0585,982,726.28
  少数股东损益-1,902.55-207.08-118.315,281,402.36
  扣除非经常损益后的净利润42,055,914.7333,435,102.117,761,653.6279,089,272.16
七、每股收益
  (一)基本每股收益0.080.060.030.14
  (二)稀释每股收益0.080.060.030.13
九、综合收益总额48,447,635.536,967,123.1519,044,700.7491,264,128.64
  归属于母公司股东的综合收益总额48,449,538.0536,967,330.2319,044,819.0585,982,726.28
  归属于少数股东的综合收益总额-1,902.55-207.08-118.315,281,402.36
公告日期2025-10-292025-08-292025-04-242025-04-24
审计意见(境内)标准无保留意见
TOP↑